title: Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
abstract: OBJECTIVE
  To investigate the response rate of the triple combination of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) and 5-fluorouracil (5-FU) and to assess its impact on secondary resectability of previously non-resectable liver metastasis (LM).
  
  
  METHODS
  Patients > or = 18 with MCRC, ECOG grade 0-2, and no prior treatment received L-OHP (85 mg/m(2)), CPT-11 (150 mg/m(2)) and 5-FU (2 250 mg/m(2) in 48 h CI) on D1 every 15 days.
  
  
  RESULTS
  Forty-seven patients with initially non-resectable metastatic disease were included. Median age 62 years (38-76); 28 males; 26 patients with 0 performance status (ECOG) 40 patients had prior surgery and four adjuvant chemotherapy. All patients were evaluable for toxicity and 42 for response. Main grade 3-4 toxicities were neutropenia (40%), febrile neutropenia (4%), diarrhea (21%), nausea/vomiting (11%/15%), fatigue (11%), anemia and alopecia (9% each); grade 3-4 neurotoxicity was observed in 28% patients. Secondary surgery was possible in 15 of 47 (31.9%) patients and 12/30 (40%) patients with only LM: in this cohort, median OS has not been reached at 22 months median follow-up, with 2/12 patients having died. Overall response rate was 69% (95% CI, 53-82%); 13 (31%) had stable disease. Median time to progression and overall survival (OS) were 10.9 (95% CI, 9.9-13.2) and 19.9 (95% CI, 11.7-TBD) months, respectively.
  
  
  CONCLUSIONS
  This combination has shown promising activity with manageable toxicity as front-line treatment in MCRC, and has allowed the resectability of LM in a considerable number of patients, offering them the possibility of long-term survival.
authors.affiliation: Institut Català Oncologia, Servicio de Oncologia Médica, Hospital Germans Trias i Pujol, Barcelona Cta. Canyet s/n, Barcelona, Spain. aabad@ico.scs.es
authors.forename: Albert
authors.initials: A
authors.lastname: Abad
authors.forename: Bartomeu
authors.initials: B
authors.lastname: Massuti
authors.forename: Antonio
authors.initials: A
authors.lastname: Antón
authors.forename: Maria Eugenia
authors.initials: ME
authors.lastname: Vega
authors.forename: Ana L
authors.initials: AL
authors.lastname: Yuste
authors.forename: Eugenio
authors.initials: E
authors.lastname: Marcuello
authors.forename: José Luis
authors.initials: JL
authors.lastname: Manzano
authors.forename: Vicente
authors.initials: V
authors.lastname: Alonso
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato
authors.forename: Mercedes
authors.initials: M
authors.lastname: Martinez-Villacampa
authors.forename: J
authors.initials: J
authors.lastname: Tabernero
authors.forename: Enrique
authors.initials: E
authors.lastname: Aranda
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivera
authors.forename: Eduardo
authors.initials: E
authors.lastname: Díaz-Rubio
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin